Goltor (Simvastatin, Ezetimibe)

Goltor is indicated for the treatment of various lipid disorders where lowering low‑density lipoprotein (LDL) cholesterol is required. It is commonly prescribed as part of a comprehensive lipid‑lowering strategy that includes diet and lifestyle changes.

• Primary hypercholesterolemia, especially when statin monotherapy is insufficient.
• Mixed dyslipidemia with elevated LDL‑C and triglycerides.
• Familial hypercholesterolemia in adults.
• Patients who require additional LDL‑C reduction beyond that achieved with a statin alone.
• Adjunct therapy in individuals with high cardiovascular risk profiles.

Goltor may cause a range of side effects, most of which are mild and transient. Serious adverse events are less common but require prompt medical attention.

Common

• Muscle aches or weakness (myalgia).
• Headache.
• Abdominal discomfort or dyspepsia.
• Elevated liver enzymes.
• Diarrhea.
• Fatigue.

Serious

• Rhabdomyolysis or severe muscle breakdown.
• Acute liver injury or hepatitis.
• Severe allergic reactions (e.g., angioedema, anaphylaxis).
• Persistent elevation of creatine kinase.
• Acute pancreatitis (rare).

Before initiating Goltor, clinicians should evaluate patient history and laboratory values to minimize risk. Specific considerations include:

• Contraindicated in pregnancy; women of childbearing potential must use effective contraception.
• Assess baseline liver function tests; avoid use in active liver disease.
• Monitor creatine kinase levels if patients report muscle symptoms.
• Caution in patients with renal impairment; dose adjustment may be needed.
• Review for potential drug interactions, especially with CYP3A4 inhibitors.
• Advise patients to report unexplained muscle pain, dark urine, or jaundice promptly.

Goltor can interact with several medication classes, influencing its efficacy or safety profile.

Avoid

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir) which can increase simvastatin exposure.
• Fibrates (gemfibrozil) that raise the risk of myopathy.
• Certain antacids containing aluminum or magnesium that may affect ezetimibe absorption.
• Warfarin, as lipid‑lowering therapy may alter INR stability.

Use with caution

• Other statins or high‑intensity lipid‑lowering agents.
• Niacin, which can increase the risk of hepatotoxicity.
• Digoxin, due to potential alterations in plasma concentrations.
• Antihypertensive agents, as blood pressure changes may be observed.